Una nueva generation de fârmacos antifungicos

Revista Iberoamericana de Micologia

Volumn 18, Issue 1, 2001, Pages 2-5

  Carrillo Muñoz, Alfonso Javier ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLUS; CANDIDA; DOSE RESPONSE; HISTOPLASMA; HUMAN; MYCOSIS; REVIEW;

EID: 0035007874     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Graybill Changing strategies for treatment of systemic mycoses. Braz J Infec Dis 2000;4:47-54.
2. Ryley JF (Ed.). Handbook of experimental pharmacology. Chemotherapy of fungal diseases. Berlin, Springer Verlag, 1990.
3. Herreros E, Martinez CM, Almela MJ, Marrito MS, de las Heras FG, GargalloViola D. Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii and filamentous fungi. Antimicrob Agents Chemother 1998;42:2863-2869.
4. Carrillo-Munoz AJ, Pemàn J, Gobernado M. Nuevos antifûngicos. Rev Esp Quimioter 1999;12:181 -204.
5. Hazen EL, Brown R, Mason A. Protective action of fungicidin (nystatin) in mice against virulence enhacing activity of oxytetracycline on Candida albicans. Antibiotics Chemother 1953; 3:1125-1128.
6. Thomas AH. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J Antimicrob Chemother 1986; 17: 269-279.
7. Ringden O, Tollemar J. Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children. Mykoses 1993; 36:187-192.
8. Grant-Prentice H. Liposomal amphotericin B in neutropenic patients. Rev Iberoam Micol 1993;10:59-61.
9. Quo KS, Fielding RM, Lasic DD, Hamilton RL, Mufson D. Novel antifungal drug delivery stable amphotericin B-cholesteril sulphate discs. Int J Pharm 1991; 75: 45-54.
10. Hirota H, Itoh A, Iwamoto Y, Goshima E, Miki T, Hasuda K. YS-822A, a new polyene macrolide antibiotic. II planar structure of YS-822. J Antibiotics 1991 ; 44: 181-186.
11. Hänel H, Schmidts H, Schrinner LE. Reduction of amphotericin B toxicity in mice by-treatment with various xanthines like pentoxifylline and HWA-448.11th ISHAM Congress. Montreal, Canada 1991:133.
12. Proffit RT, Sartorius A, Chiang SM, Sullivan L, Adler-Moore JP. Pharmacology and toxicology of a liposomal formulation of amphotericin B AmBisome in rodents. J Antimicrob Chemother 1991:28:49-61
13. Walsh TJ, Hiemenz JW. Seibel NL, et al. Amphotericin B lipid complex lor invasive fungal infections: analysis of efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-1396.
14. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603-618.
15. Van Etten EW, Snijders SV, Van Viannen W, Bakker-Woudenberg IA. Supperior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice. Antimicrob Agents Chemother 1998; 42:2431-2433.
16. Wingard Efficacy of amphqtericin B lipid complex injection (ABLC) in bone marrow transplant recipients with lifethreatening systemic mycoses. Bone Marrow Transplant 1997; 19:343-347.
17. Adedoyin A, Bernardp JF, Svenson CF, et al. Pharmakokinetic profile of Abelcet (amphoteriecin B lipid complex injection) combined experience from phase I and phase II studies. Antimicrob Agents Chemother 1997; 41: 2201-2208.
18. De Marie S. Liposomal and lipid-based formulations of amphotericin B. Leukemia 1996;10 (Suppl.2):93-96.
19. Dix SP, Wingard Amphotericin B lipid complex: review of safety, pharmacokinetics and efficacy. Drugs of Today 1996; 32 (Suppl.G): 19-25.
20. demons KV, Stevens DA. Comparison of Fungizone, Amphotec, Ambisome and Abelcet for treatment 9! systemic murine cryptococcosis. Antimicrob Agents Chemother 1998; 42: 899-902.
21. Carrillo-Munoz AJ, Quindos G, Tür C, et al. In vitro antifungal activity of lipospmal nystatin in comparison with nystatin, amphotericin B choiesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycnolate, Iluconazole and itraconazole. J Antimicrob Chemother 1999; 44:397-401.
22. Alonso-Vargas R, Gonzalez-Alvarez L, Ruesga MT, eraJ. Actividad in vitro de una formulacion liposomica de nistatina (Nyotran®) (rente a Cryptococcus neoformans. Rev Iberoam Micol 2000:17:90-92.
23. Quindos G, Carrillo-Munoz AJ, Ruesga MT, etal. In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens. Eur J Clin Microbiol Infect Dis 2000:19:645-648.
24. Quindos G, Carrillo-Munoz AJ, Arévalo MP, etal. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy 2000; 46:395-401.
25. Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of In vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother 1998:42:1412-1416.
26. Wallace TL, Lopez-Berenstein G. Nystatin and liposomal nystatin. En: Yu VL, Merigan TC, Barriere S, White NJ (Eds.). Antimicrobial therapy and vaccines. Baltimore, Williams and Wilkins, 1998:1185-1191.
27. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical avaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41:2326-2332.
28. Barchiesi F, Schimmizzi AM, Caselli F, etal. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44; 2435-2441.
29. Klepser ME, Hoffman HL, Erns EJ. Novel triazqle antifungal agents. Expert Opin Investig Drugs 2000; 9:593-605.
30. Ghannoum MA, Hossain MA. New investigational antifungal agents for treatening invasive fungal infections. Expert Opin Drugs 2000; 9:1797-1813.
31. Patterson TF. The role of newer azoles in surgical patients. J Chemother 1999; 11:504-512.
32. Graybill New antifungal agents. Eur J Clin Microbiol Infect Dis 1989; 8: 402-412.
33. Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK 109.496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997;41:2491-2496.
34. Marco F, Pfaller MA, Messer S, Jones RN. In vitro activities of voriconazole (UK 109.496) and four pther antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 1998:42:161-163.
35. Kauffman ÇA, Zarins LT. In vitro activity of voriconazole against Candida species. Diagn Microbiol Infect Dis 1998;31:297300.
36. Espinel-lngroff A. In vitro of the new triazole voriconazole (UK-109.496) against opportunistic filamentous and dimorphic fungi and commond and emerging yeast pathogens. J Clin Microbiol 1998:36:198-202.
37. Barry AL, Brown S. In vitro studies of two triazole antigungal agents (voriconazole (UK-109,496 and fluconazole) against Candida species. Antimicrob Agents Chemother 1996;40:1948-1948.
38. Rhunke M, Schmidt-Westhhausen A, Trautman M. In vitro activities of voriconazole (UK-109,496} against fluconazole-susceptible and resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infections. Antimicrob Agents Chemoter 1997;41:575-577.
39. Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Asperglllus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997;41:696-698.
40. Barchiesi F, Arzeni D, Fothergill AW, et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 2000;44: 226-229.
41. Espinel-lngroff A. Germinated and non-germinated conidial suspensions for testing os susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole and voriconazole. Antimicrob Agents Chemother 2001:45: 605-607.
42. Luttz JE, demons KV, Aristizabal BH, Stevens DA. Activity of SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother 1997:41:1558-1561.
43. Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Loebenberg D, Rex JH. Treatment of murine fusariosis with SCH-56592. Antimicrob Agents Chemother 1999:43:589-591.
44. Connolly P, Wheat J, Schnizlein Bick C, et al. Comparison of new triazole antifungal agent, Schering 56592, with iraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother 1999;43:322-328.
45. Nomeir AA, Kumari P, Hubert MJ, et al. Pharmacokinetics of SCH 56592, a new azole broad spectrum antifungal agent, in mice, rats, rabbits, dogs and cynomolgus monkeys. Antimicrob Agents Chemother 2000;44:727-731.
46. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000:46:229-234.
47. Cacciapuoti A, Loebenberg D, Corcoran E, ef al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent against Aspergillus and Candida. Antimicrob Agents Chemother 2000:44:2017-2022.
48. AI-Abdely HM, Najvar L, Bocanegra R, et al. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaehyphomycosis due to Rarnichloridium obovoldeum (Ramich/oridium mackenziei). Antimicrob Agents Chemother 2000;44:1159-1162.
49. Connolly P, Wheat LJ, SchnizieinBick C, ef al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for the treatment of histoplasmosis following pulmonary challenge in inmmunocompromised mice. Antimicrob Agents Chemother 2000:44:2604-2608.
50. Abruzzo GK, Gill CJ, Flattery AM, ef al. Efficacy of the echinocandin caspofungin against disseminated aspergilosis and candidiasis in cyclophosphamide-induced immunocompressed mice. Antimicob Agents Chemother 2000;44: 2310-2318.
51. Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K. Efficacy of ER30346, a novel oral triazole antifungal agents, in experimental models of aspergillosis, candidiasis and crytococcosis. Antimicrob Agents Chemother 1996:40:2243-2247.
52. Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RRJ, Jones RN. In vitro activities of rayuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2000:44:2883-2886.
53. Georgopapadakou NH. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs 2001 ;10:269-280.
54. Ernst EJ, Klepser ME, Messer SA, Pfaller MA. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999:33:75-80.
55. Barchiesi F, Schimizzi AM, Fothergill AW, Scalise G, Rinaldi MG. In vitro activity of the new echinocandin antifungal MK0991 against common and uncommon clinical isolates of Candida species. Eur J Microbiol Infect Dis 1999;18:302-304.
56. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two new derivatives, LY303366 and MK-0991 (L-743,792) against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi. Diagn Microbiol Infect Dis. 1998:30:251-255.
57. Groll AH, Guliick BM, Petraitiene R, et al. Compartimentai pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother 2001 ;45:596-600.
58. Espinel-lngroff, A. Comparison of in vitro activities of the new triazole SCH 56592 and the echinocandins MK-0991 (L-743.872) and LY303366 against opportunistic filamentous fungi and dimorphic fungi and yeasts. J Clin Microbiol 1998:36:2950-2956.
59. Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743.872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998:42:1985-1989.
60. Pelaez F, Cabello A, Platas G, et al. The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Sys Appl Microbiol 2000:23:333-343.
61. Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and singledose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergilosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998:42:2898-2905.
62. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of tow new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366 in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000:44:3381-3318.
63. Zornes LL, Stratford RE. Development of a plasma high performance liquid Chromatographie assay for LY303366, a lipopeptide antifungal agentand its application in a dog pharmacokinetic study. J Chromatogr B Biomed Sei Appl 1997;695:381-387.